Cargando…
Metabolic imaging using hyperpolarized (13)C‐pyruvate to assess sensitivity to the B‐Raf inhibitor vemurafenib in melanoma cells and xenografts
Nearly all melanoma patients with a BRAF‐activating mutation will develop resistance after an initial clinical benefit from BRAF inhibition (BRAFi). The aim of this work is to evaluate whether metabolic imaging using hyperpolarized (HP) (13)C pyruvate can serve as a metabolic marker of early respons...
Autores principales: | Acciardo, Stefania, Mignion, Lionel, Lacomblez, Estelle, Schoonjans, Céline, Joudiou, Nicolas, Gourgue, Florian, Bouzin, Caroline, Baurain, Jean‐François, Gallez, Bernard, Jordan, Bénédicte F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991684/ https://www.ncbi.nlm.nih.gov/pubmed/31833658 http://dx.doi.org/10.1111/jcmm.14890 |
Ejemplares similares
-
Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018) -
Hyperpolarized (13)C-Pyruvate to Assess Response to Anti-PD1 Immune Checkpoint Inhibition in YUMMER 1.7 Melanoma Xenografts
por: Farah, Chantale, et al.
Publicado: (2023) -
Combined HP (13)C Pyruvate and (13)C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts
por: Farah, Chantale, et al.
Publicado: (2022) -
Obesity and triple‐negative‐breast‐cancer: Is apelin a new key target?
por: Gourgue, Florian, et al.
Publicado: (2020) -
Impact of Inhibition of the Mitochondrial Pyruvate Carrier on the Tumor Extracellular pH as Measured by CEST-MRI
por: Buyse, Chloé, et al.
Publicado: (2021)